Summary of Orthofix Medical FY Conference Call Company Overview - **Company**: Orthofix Medical (NasdaqGS: OFIX) - **Date of Conference**: March 03, 2026 - **Key Speakers**: Matt Blackman (TD Cowen), Julie Andrews (CFO), Julie Dewey Key Points Company Positioning and Transformation - Orthofix inherited a company with strong assets but a weak operating model and financial profile, which were not conducive to sustainable growth [3][4] - The company underwent significant management and portfolio overhauls, focusing on financial health and operational efficiency [2][3] - The SeaSpine merger introduced innovation but also complexity and cash burn, necessitating a reset of the business foundation [3][4] Financial Performance and Growth Strategy - The company has shifted focus towards profitable growth, optimizing capital allocation and commercial footprint [6] - Over 75% of U.S. spine sales now come from the top 30 distributors, up from less than half in early 2024, leading to improved execution and predictability [6][16] - Debt refinancing in November 2024 improved liquidity and capital access, supporting long-term growth [7] - Orthofix has achieved eight consecutive quarters of EBITDA margin expansion, moving from a cash burn of over $100 million in 2023 to nearly breakeven in 2025 [8] Future Projections - The company targets a net sales CAGR of 6.5% to 7.5% from 2026 to 2028, with an adjusted EBITDA margin in the mid-teens by 2028 [22] - The growth will be driven by capturing benefits from distributor transitions, a strong innovation pipeline, and new product launches [27][28] Product Launches and Innovation - Orthofix plans over a dozen product launches in the next 18 months, including the Verata Open and Verata MIS platforms, which are expected to drive multi-year growth [7][28] - The company is also focusing on enhancing its Limb Reconstruction business, which has a significant market opportunity of $2.6 billion [88] Market Dynamics and Competitive Position - The Bone Growth Therapy (BGT) segment holds over 50% market share in the spine segment and is positioned for further growth in the fracture market, which is valued at approximately $250 million [60][67] - The Limb Reconstruction business is expected to return to double-digit growth, supported by new product launches and a focused commercial strategy [89] Challenges and Considerations - Legal expenses related to the former leadership team are expected to decrease, which has been a headwind for free cash flow [37][41] - The company is managing a 1% headwind in Q1 due to timing of utilization, but this is not expected to affect physician prescribing behavior [75][86] Conclusion - Orthofix is positioned for significant growth driven by operational improvements, a strong innovation pipeline, and a more efficient commercial strategy [52][112] - The company believes it is fundamentally stronger than two years ago, with a favorable outlook for future performance [112]

Core Insights - Orthofix reported strong performance in Q4 2025, with significant growth in Bone Growth Therapies and U.S. Limb Reconstruction, marking the eighth consecutive quarter of adjusted EBITDA growth [6] Sales Performance - Total global net sales for Q4 were $218.6 million, reflecting a 3% increase on a pro forma, constant-currency basis, excluding discontinued M6 artificial disc product lines [4] - The top 30 U.S. distributor partners contributed to a 25% year-over-year growth in net sales for Q4, with over 75% of U.S. net sales driven by these partners by Q4 2025 [1] Segment Performance - Global limb reconstruction net sales reached $38.0 million, driven by an 8% growth in the U.S. [2] - Bone Growth Therapies achieved Q4 net sales of $68.3 million, up 7%, benefiting from increased utilization and higher prescribing velocity [2] - Global spinal implants, biologics, and enabling technologies reported Q4 net sales of $112.3 million, supported by targeted distributor transitions [3] Product Developments - Orthofix plans to launch the VIRATA Spinal Fixation System in the second half of 2026, integrating it with the 7D navigation platform [7] - The company expects to introduce over a dozen products in the next 18 months, focusing on automation enhancements and technology-enabled advancements [9] Financial Metrics - Q4 pro forma non-GAAP adjusted gross margin was 71.4%, with a Q4 adjusted EBITDA of $29.2 million, representing 13.4% of net sales [10][11] - Free cash flow for Q4 was $16.8 million, with total cash at the end of the quarter amounting to $85.1 million [11] Future Guidance - For 2026, Orthofix guided net sales of $850 million to $860 million, implying approximately 5.5% pro forma constant-currency growth [12] - The company anticipates positive free cash flow for 2026, excluding potential legal settlements, and expects an adjusted gross margin of approximately 72.5% [13]

Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [13] - Pro forma non-GAAP Adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [14] - U.S. Limb Reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4][5] Market Data and Key Metrics Changes - U.S. Limb Reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The BGT business delivered strong sequential fourth quarter growth, reaching 7%, more than double the market rate [8] - The company expects to return to double-digit growth in the second half of 2026 for U.S. Limb Reconstruction as portfolio refinements take hold [14] Company Strategy and Development Direction - The company has rebranded its orthopedics business as Limb Reconstruction, focusing on high-value clinical categories with an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization, extending the timeline to 2028 [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by a focused distributor network and innovation pipeline [11][25] - The company is committed to disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [24][27] - Management highlighted the importance of ongoing product launches and enhancements across all business segments to drive sustained momentum [26] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [17] - Adjusted gross margins for the full year 2026 are expected to be approximately 72.5% [18] - The company anticipates $45 million-$50 million in capital expenditures for the year [22] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [32] Question: Long-range plan and margin improvement - Management explained that the extended timeline reflects the need for a stronger foundation and focus on market execution, with ongoing efforts to improve gross margins and cash generation [34][37] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with a return to double-digit growth in the second half of 2026 for limb reconstruction [42] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and emphasized a renewed focus on advancing the biologics portfolio [51][52] Question: Tariff impact and legal settlements - Management indicated an expected $1 million-$2 million impact from tariffs in 2026 and confirmed that an accrual for a legal settlement was taken in Q3 [57][62]

Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [13] - Pro forma non-GAAP adjusted gross margin was 71.4%, reflecting the impact of the M6 discontinuation and productivity improvements [15] - Fourth quarter pro forma non-GAAP adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [14] - U.S. limb reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4][14] Market Data and Key Metrics Changes - U.S. limb reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The BGT business delivered fourth quarter growth of 7%, more than double the market rate [8] Company Strategy and Development Direction - The company is focused on enhancing its commercial execution and driving deeper market penetration of the 7D navigation system [8] - A strategic rebranding of the orthopedics business to limb reconstruction reflects a focus on high-value clinical categories, representing an estimated $2.6 billion market opportunity [6] - The company plans to launch the VIRATA Spinal Fixation System in the second half of 2026, which is expected to enhance surgical efficiency and serve as a multi-year growth catalyst [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth [11] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization [10] - Management highlighted the importance of maintaining disciplined execution and targeted capital allocation to achieve sustainable above-market growth [10][11] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [17] - Adjusted growth margins for the full year are expected to be approximately 72.5% [18] Q&A Session Summary Question: Clarification on CMS impact on BGT - The CMS change is expected to have a 1% impact in Q1 specific to BGT revenue only, which is immaterial for the year overall [32] Question: Long-range plan and margin improvement - Management indicated that the channel optimization initiative took longer to execute, but it is expected to strengthen the foundation for long-term value [34][37] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with U.S. limb reconstruction returning to double-digit growth in the second half of 2026 [42] Question: 7D placements and biologics portfolio - There was a 30% increase in 7D placements in 2025, and the biologics portfolio is expected to regain market pace as the commercial network is scaled [51][53] Question: Tariff impact on guidance - The company expects about a $1 million-$2 million impact from tariffs in 2026, which is included in the guidance [57] Question: Free cash flow improvement expectations - Free cash flow improvement from 2025 to 2026 is expected to be in the range of $7 million-$8 million, excluding legal settlements [60]

Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [12] - Pro forma non-GAAP adjusted gross margin was 71.4%, reflecting the impact of the M6 discontinuation and productivity improvements [15] - Fourth quarter pro forma non-GAAP adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4] - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [13] - U.S. limb reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] Market Data and Key Metrics Changes - U.S. limb reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The spine commercial channel optimization efforts led to a 25% year-over-year growth in net sales from the top 30 U.S. distributor partners [5] Company Strategy and Development Direction - The company has rebranded its orthopedics business as limb reconstruction, focusing on four high-value clinical categories, representing an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a multi-year growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by new product launches and improved distributor performance [11] - The company expects to deliver durable top-line growth, expanding margins, and strong free cash flow in 2026 [9] - Management highlighted the importance of disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [22] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [16] - Adjusted growth margins for the full year are expected to be approximately 72.5% [19] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [31] Question: Long-range plan (LRP) and margin improvement - Management indicated that the delay in the LRP reflects the extensive work done to strengthen the foundation and optimize the distributor transition [32][33] - They emphasized the focus on gross margin expansion and productivity improvements to achieve mid-teens EBITDA and positive free cash flow [35] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with U.S. limb reconstruction returning to double-digit growth in the second half of 2026 [40] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and expressed confidence in the biologics portfolio's potential for recovery and growth [48][50] Question: Tariff impact and legal settlements - Management confirmed that the tariff impact is included in the 2026 guidance, expecting about $1 million-$2 million impact [54] - They acknowledged having taken an accrual for a legal settlement in Q3 [56]

Financial Data and Key Metrics Changes - Total global net sales reached $203.4 million, a 6% increase over the prior year, driven by strong performance in US spine and orthopedic segments [13] - Pro forma non-GAAP adjusted gross margin reached 72.1%, up 80 basis points from Q3 2024, driven by the discontinuation of M6 and productivity improvements [15] - Pro forma non-GAAP adjusted EBITDA was $24.6 million, or 12.1% of net sales, with year-over-year margin expansion of 230 basis points [16] - Generated positive free cash flow of $2.5 million, ending the quarter with $65.9 million in total cash [16] Business Line Data and Key Metrics Changes - US spine fixation segment net sales increased 8%, with procedural volume up 10% [5] - US orthopedics grew 19%, marking the fifth consecutive quarter of double-digit growth [9] - Bone Growth Therapies (BGT) achieved $61.2 million in net sales, reflecting 6% growth [15] Market Data and Key Metrics Changes - International spine fixation net sales grew by 86% year-over-year [14] - The US pedicle screw market, valued at approximately $2 billion in 2025, is projected to grow at a steady 4%-5% compound annual growth rate through 2030 [8] Company Strategy and Development Direction - Focus on sharpening commercial execution, improving gross margin, and maintaining disciplined capital allocation [10] - Advancing a data-driven deformity strategy with access to pre-operative planning and patient-specific roads beginning in Q1 of next year [9] - Aiming for a full launch of the Virada Spinal Fixation System in the second half of next year [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver strong operational and financial performance through the remainder of 2025 [19] - The company is well-positioned for its next phase of profitable growth with a streamlined product portfolio and optimized commercial channel [10] - Anticipated continued momentum in spine, BGT, and orthopedics businesses supported by a robust innovation pipeline [18] Other Important Information - The company is raising the bottom end of its full-year 2025 pro forma non-GAAP adjusted EBITDA guidance range to $84 million, with an updated range of $84 million-$86 million [17] - The guidance excludes revenue from the discontinued M6 product lines and implies fourth-quarter pro forma net sales will be approximately $219 million [17] Q&A Session Summary Question: Near-term revenue guidance and Q4 expectations - Management indicated that guidance was set appropriately, considering a strong Q4 last year and comparability issues [23] Question: Long-term financial targets for 2027 - Management suggested that growth will be more weighted towards 2027, driven by the full launch of Virada and continued acceleration of TrueLok Elevate [25] Question: Key drivers of strong results in US spine - Management identified three key points: distributor transitions, innovation pipeline, and the success of the 7D technology [32] Question: Q4 free cash flow expectations - Management expects to be free cash flow positive for the second half of 2025 but does not anticipate exceeding last year's Q4 figure [34] Question: Distributor transitions and increases - Management explained that the transition involves both consolidation and expansion of distributors to enhance market presence [37] Question: Clinical validation of TrueLok Elevate - Management expressed confidence in clinical validation efforts and the potential for more studies and publications in the future [40]